M1 Kliniken Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Attila Strauss

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	2yrs
CEO ownership	n/a
Management average tenure	no data
Board average tenure	2.1yrs

Recent management updates

Recent updates

CEO

Attila Strauss

2yrs

Tenure

Mr. Attila Strauss is Member of Management Board & Chief Executive Officer of M1 Kliniken AG since November 24, 2022 and March 2023 respectively. He studied International Trade Management (B.A.) and Inform...

Board Members

Name	Position	Tenure	Compensation	Ownership
Sabine Meck	Member of Supervisory Board	9.4yrs	no data	no data
Uwe Zimdars	Chairman of Supervisory Board	2.1yrs	no data	no data
Dirk Hempel	Deputy Chairman of Supervisory Board	2.1yrs	no data	no data

2.1yrs

Average Tenure

Experienced Board: M12's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.

M1 Kliniken Management

Management criteria checks 0/4

Key information

Recent management updates

M1 Kliniken AG, Annual General Meeting, Jul 17, 2024

M1 Kliniken AG, Annual General Meeting, Jul 13, 2022

M1 Kliniken AG Announces Resignation of Patrick Brenske from the Management Board

Recent updates

New major risk - Revenue size

Investor sentiment improves as stock rises 16%

New major risk - Share price stability

Upcoming dividend of €0.50 per share

Now 21% undervalued

Investor sentiment deteriorates as stock falls 15%

M1 Kliniken AG, Annual General Meeting, Jul 17, 2024

Price target increased by 57% to €27.50

Full year 2023 earnings released: EPS: €0.54 (vs €0.24 in FY 2022)

Investor sentiment improves as stock rises 19%

Investor sentiment improves as stock rises 16%

New minor risk - Financial data availability

Investor sentiment improves as stock rises 15%

New minor risk - Share price stability

Price target increased by 14% to €14.35

Now 21% undervalued

Now 20% undervalued

Price target increased by 10% to €11.85

First half 2023 earnings released: EPS: €0.17 (vs €0.07 in 1H 2022)

Now 20% undervalued

Now 20% undervalued

Now 20% undervalued

New minor risk - Profit margin trend

Full year 2022 earnings: EPS misses analyst expectations

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 16%

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Price target decreased to €10.85

Investor sentiment deteriorated over the past week

M1 Kliniken AG, Annual General Meeting, Jul 13, 2022

Full year 2021 earnings: Revenues miss analyst expectations

Price target decreased to €14.00

M1 Kliniken AG to Report Fiscal Year 2021 Final Results on May 19, 2022

Now 24% undervalued after recent price drop

Now 20% undervalued after recent price drop

Investor sentiment improved over the past week

Price target increased to €20.00

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS €0.37 (vs €0.56 in FY 2019)

New 90-day high: €9.60

Price target lowered to €16.40

M1 Kliniken AG Announces Resignation of Patrick Brenske from the Management Board

Market bids up stock over the past week

New 90-day low: €8.10

M1 Kliniken AG (XTRA:M12) completed the acquisition of 48.16% stake in HAEMATO AG (XTRA:HAE) from MPH Health Care AG (XTRA:93M).

First half earnings released

New 90-day low - €8.92

New 90-day low - €9.04

CEO

Tenure

Board Members

Average Tenure